Compare Philip Morris International Inc. (PM) vs Stryker Corporation (SYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Philip Morris International Inc. vs Stryker Corporation — how do they compare? Philip Morris International Inc. trades at $200.2 (market cap $312.50B), while Stryker Corporation trades at $276.85 (market cap $106.24B). The key difference: Philip Morris International Inc. is far larger — about 2.9× Stryker Corporation's market cap, and Philip Morris International Inc. pays the higher dividend (3.19%). Which is the better fit depends on your goals — on Pluang, investors hold Philip Morris International Inc. for 85 Days and Stryker Corporation for 20 Days on average.
| PM | SYK | |
|---|---|---|
Market Cap | $312.50B | $106.24B |
Volume | 5,517,172 | 2,982,001 |
Sector | Consumer Staples | Health |
52-Week High | $200.50 | $388.35 |
52-Week Low | $144.33 | $269.75 |
Typical Hold Time | 85 Days | 20 Days |
Enterprise Value | $355.62B | $117.70B |
Dividend Yield | 3.19% | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Philip Morris International (PM) trades at $200.5, up 5.3% over 24 hours, with a bullish technical signal and strong earnings beats in Q1 and Q2 2026. The company shows robust fundamentals with 2025 revenue of $40.65B and net income of $11.35B, supported by a 67.48% gross margin. Recent news highlights expansion of smoke-free products like ZYN and IQOS, now over 40% of revenue, driving growth amid industry shifts.
Outlook is positive with analyst consensus at Buy (68%) and a $212.17 price target, though elevated P/E of 26.46 and regulatory risks in tobacco remain concerns. Earnings growth and smoke-free product adoption are key catalysts, but investors should monitor debt levels and competitive pressures.
Stryker (SYK) trades at $275.4, down 1.11% amid a bearish technical signal and negative news flow. The company maintains strong profitability with a 14.43% net margin and a 71% analyst buy rating, but faces headwinds from a manufacturing issue disclosure that triggered an 8.8% stock drop on September 8, 2026. Q3 2026 earnings are due October 29, 2026, following a mixed earnings history with a recent miss in Q1 2026.
The stock presents a divergence between solid fundamentals and near-term sentiment risks. The consensus price target of $368.11 implies significant upside, but ongoing legal investigations and operational challenges pose risks to investor confidence. Earnings growth and resolution of manufacturing issues are critical for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Philip Morris International Inc.
Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
